Common questions about Deflux-DT (FAQ)
Q: Is Deflux-DT a drug, a medical device, or an implant?
According to official product information, Deflux is classified by the FDA as a medical device. Specifically, it is an injectable bulking agent that is used as an implant for treating Vesicoureteral Reflux (VUR).
Q: What are the primary differences between Deflux-DT and long-term antibiotic therapy for VUR?
Official information indicates that Deflux is described as a minimally invasive procedure designed to provide mechanical correction of the reflux issue. In contrast, antibiotic therapy is a long-term medication used to suppress infections while the patient is monitored for potential spontaneous resolution of the reflux.
Q: Is Deflux-DT also sometimes used to treat urinary incontinence in adults or children?
While the primary FDA approval is for VUR Grades II–IV, the device's classification is that of an injectable bulking agent. This category of device materials have been described in the same regulatory category for use in conditions like stress urinary incontinence (SUI).
Q: What materials are the components of the Deflux-DT injection gel made of?
The injection gel is composed of two specific cross-linked sugar molecules (polysaccharides). These components are dextranomer microspheres and hyaluronic acid (HA), which form the injectable material.
Q: Are the materials in Deflux-DT similar to anything naturally found in the body?
Yes, one of the primary components, hyaluronic acid, is described in official material information as chemically similar to components the body produces naturally. This component is designed to be gradually replaced by the body's own tissue.
Q: How long is the Deflux-DT implant expected to remain effective?
The implant is designed to provide long-term structural stability to the ureter. Research studies tracking patients have reported successful outcomes and absence of long-term safety issues over follow-up periods of up to 25 years.
Q: Will a child's natural growth affect the long-term effectiveness of Deflux-DT?
Official descriptions state the implant is designed to be durable as the child grows. This is because the injected material is eventually replaced by the child's own stable, collagen-forming tissue.
Q: Is it normal to experience a burning or stinging sensation when urinating right after the Deflux-DT procedure?
Mild stinging or discomfort during urination (dysuria) is noted in patient information leaflets as a common and expected reaction immediately following the procedure. These symptoms are generally temporary and are expected to resolve within one to two days.
Q: How common is it to see pink-tinged urine or blood in the urine after the injection?
Seeing pink-tinged urine or small amounts of blood in the urine (haematuria) is a common and expected reaction. This is associated with the use of the cystoscope during the procedure and should generally resolve naturally within one to two days according to patient leaflets.
Q: How long after the procedure should the frequent urge to urinate or bedwetting stop?
Urgency and frequency of urination are reported as temporary adverse events in official documentation. Official documentation states these symptoms are generally temporary and are often reported to resolve in a day or two after the procedure.
Q: What are the signs of a serious complication like ureteral blockage after Deflux-DT?
Official warnings advise contacting a healthcare professional immediately if the patient experiences a severe fever, severe belly or back pain, or is unable to urinate. These symptoms could be an indication of a potential ureteral blockage.
Q: Does the Deflux-DT injection increase the chance of getting a urinary tract infection (UTI)?
Urinary tract infection (UTI) is listed as a reported adverse event in clinical studies. It is noted that UTIs are more likely, and official information indicates that the risk remains higher if the reflux is not completely resolved after the treatment.
Q: Can the Deflux-DT procedure cause a fever that requires contacting a doctor?
Yes, a fever higher than 101.5 F (sim 38.6 C) is a symptom for which the official precautions advise contacting the healthcare provider immediately.
Q: What is the risk of the gel causing an obstruction in the ureter?
Blockage of the ureters is a reported adverse event, though it occurred in a low percentage (le 1%) in clinical studies. If this occurs, it may require a further medical procedure to resolve the obstruction.
Q: What does a 'foreign body reaction' related to the Deflux-DT material mean?
A foreign body reaction is listed as a reported adverse event associated with the implant material. This medical term describes the body’s expected localized cellular response to the presence of a permanent implant material.
Q: Are there any known long-term side effects that have been reported with Deflux-DT?
Long-term follow-up studies have reported that few patients experienced long-term safety issues. One rare adverse event reported in long-term follow-up was calcification around the implantation site.
Q: Can abdominal or flank pain occur as a result of the Deflux-DT procedure?
Severe belly, back, or side pain is listed in the official warnings and precautions. This symptom is important because it could be an indication of a potential obstruction, and official precautions advise contacting the healthcare provider if this occurs.
Q: Who is generally not eligible to be treated with the Deflux-DT procedure?
Official product information states that Deflux is contraindicated in patients with specific conditions. These include having a non-functional kidney, Hutch diverticulum, ureterocele, or an ongoing urinary tract infection (UTI).
Q: Why is having an active urinary tract infection a contraindication for the procedure?
Official warnings state that treatment should be deferred until an active UTI has completely resolved. This is because performing the injection with an ongoing infection may lead to the injection site becoming infected.
Q: What specific conditions like 'Hutch diverticulum' or 'ureterocele' affect Deflux-DT eligibility?
Official patient information lists Hutch diverticulum (an abnormal bladder wall pouch) and ureterocele (swelling at the bottom of the ureter) as specific conditions for which Deflux is contraindicated.
Q: Is Deflux-DT only recommended for VUR grades II through IV?
Yes, the FDA approval for Deflux is specifically indicated for the treatment of children with Vesicoureteral Reflux (VUR) Grades II through IV.
Q: Why might a patient need more than one Deflux-DT injection?
According to official summaries, additional injections may be required if the VUR persists or is not completely resolved after the initial treatment procedure.
Q: What is the expected success rate after a single Deflux-DT treatment?
Clinical studies report a variable range of radiographic success rates for VUR resolution after one injection. The success rate can depend on the VUR grade and the specific injection technique used.
Q: How is the success of the Deflux-DT procedure confirmed in follow-up appointments?
The resolution of VUR and the success of the procedure is typically monitored and confirmed through a follow-up diagnostic imaging test called a Voiding Cystourethrogram (VCUG).
Q: Is a follow-up Voiding Cystourethrogram (VCUG) always required after the Deflux-DT procedure?
While not explicitly stated as 'always required', a follow-up VCUG is the diagnostic tool typically used in clinical practice and studies to confirm the resolution of VUR.
Q: How does the recovery time for Deflux-DT compare to open surgery for VUR?
The Deflux procedure is associated with a shorter recovery time compared to open VUR surgery. Patients are often advised to return to normal activities within one day.
Q: What is the typical length of the Deflux-DT procedure under general anesthesia?
The injection procedure is typically considered brief, usually lasting less than 30 minutes in total, and is performed using general anesthesia.
Q: What is a cystoscope and how is it used to administer Deflux-DT?
A cystoscope is a thin viewing instrument that is inserted through the urethra to see inside the bladder. It is used to allow the doctor to precisely inject and place the material at the ureteral opening.
Q: What is the difference between the STING and HIT injection techniques sometimes used with Deflux-DT?
Official documents and supporting research note that the injection technique influences outcomes. These techniques, such as the STING and HIT methods, are simply standardized ways of placing the material at the ureteral opening.
Q: Can the Deflux-DT injection be seen on diagnostic imaging scans years after the procedure?
Official safety information advises that patients should inform future doctors of the procedure. This is because the implant can sometimes be seen on X-ray and other medical imaging scans years after the treatment.
Q: Do studies suggest Deflux-DT is less effective for the most severe grades of VUR?
Research evidence indicates that radiographic cure rates for VUR resolution are reported to be lower when treating the most severe grades of reflux (such as Grade IV) compared to lower VUR grades.
Q: What is the role of the hyaluronic acid carrier gel in the function of the implant?
The hyaluronic acid component acts as a temporary fluid carrier for the dextranomer microspheres. It is designed to break down naturally after injection and is then replaced by the body’s own tissue.
Q: Can the Deflux-DT implant cause bladder spasms or a feeling of cramping?
Bladder spasms (a feeling of cramping or a strong urge to urinate) are listed as a common post-procedure reaction. This is generally a temporary symptom that is expected to resolve naturally within a day or two.
Q: Are there any known interactions between the Deflux-DT materials and other prescription medications?
Official product labeling for the implant is focused on contraindications related to the patient's existing conditions. It does not list any specific drug-to-implant material interactions that would alter the material's function.
Q: Does Deflux-DT require a hospital stay, or is it an outpatient procedure?
The procedure is generally performed in a day surgery setting and is considered an outpatient procedure. This means an overnight hospital stay is typically not required.
Q: What does it mean if the ureteral opening is no longer hydrodistending after the injection?
The mechanism of the injection is to achieve coaptation (bulking and closure) of the ureter opening. The desired effect is the prevention of hydrodistension (widening/ballooning) of the opening during increased bladder pressure, which is what stops the reflux.
Q: What is the typical time frame to see if the Deflux-DT procedure was successful?
The success of the procedure is typically evaluated through follow-up diagnostic imaging, most commonly a VCUG, which is often performed approximately six weeks postoperatively.
Q: What happens if the bulge created by Deflux-DT is too large?
Official warnings state that injecting too much Deflux is associated with the potential for a blockage in the ureter (obstruction). This may require a separate medical procedure to correct.
Q: Is there a different set of risks when Deflux-DT is used in adults versus children?
The primary FDA approval (PMA) for Deflux is specifically indicated for the treatment of children with VUR Grades II–IV. Safety and efficacy studies focus on this patient population.
Q: How long has the Deflux-DT product been available and used for VUR treatment?
Deflux has been used in Europe since 1998 and was approved by the FDA in the United States in 2001 for the treatment of VUR.
Q: Is Deflux-DT considered a permanent or temporary solution for VUR?
Deflux is described as providing long-term structural stabilization. The initial hyaluronic acid carrier is replaced by the patient's own tissue, which is what provides the sustained effectiveness against VUR.
Q: Is there any difference in how Deflux-DT works for unilateral versus bilateral VUR?
Clinical studies and standard practice documents report the treatment of patients with unilateral and bilateral reflux. The physical mechanism of action remains the same regardless of whether one or both ureters are treated.
Q: What are the typical post-procedure instructions for fluid intake and activity level?
Post-procedure guidance commonly includes instructions to encourage plenty of fluids to help ease any temporary urinary symptoms. Patients are generally advised to return to normal activities within one day.
Q: Is there an age limit for children who can receive the Deflux-DT injection?
Official safety information notes that the safety and efficacy of the treatment have not been established in children under 1 year of age.
Q: What should a caregiver do if a child refuses to urinate after the procedure?
Official precautions recommend contacting the hospital if the patient does not want to urinate or has not voided in eight to ten hours. This is because the symptom may be a warning sign of a blockage.
Q: How does Deflux-DT affect follow-up monitoring for kidney health?
Due to the potential risk of ureteral obstruction, official guidance supports initial sonographic surveillance (ultrasound) to monitor the kidneys. Repeat imaging is recommended for symptomatic patients to check for any swelling or blockage.
Q: Is there a risk of the gel migrating or moving from the injection site?
The material, which includes cross-linked dextranomer, is generally described in product information as non-migratory. It is specifically designed to remain at the injection site to provide structural stabilization.
